← Analyst Upside
AU · rank #3 · 2026-05-15
PRLD
NASDAQ · $356M
verdict · CAUTION
Why this pick · factor scores
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 3.036 |
| EPS revisions (30d) Net up-revisions in consensus EPS over the past month. | -91.00% |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $12,499,999 across 1 unique buyers. | 8.366 |
| Analyst upside Consensus target $6.88 | +53.8% |
| Momentum acceleration 3-month minus 12-month momentum. | +6.18% |
| Analyst rating 1 = Strong Buy, 5 = Strong Sell. | 3.75 |
| Gross margin TTM | +100.0% |
| 52w high | $5.54 |
| Market cap | $356M |
AI research card
Independent qualitative review before order placement.
Summary
Prelude Therapeutics Inc. is a clinical-stage precision oncology company focused on discovering and developing novel small molecule cancer medicines for patients with high unmet medical needs.
Rationale
The significant analyst upside of 53.80% and recent substantial insider buying totaling nearly $12.5 million by a director suggest strong conviction in future performance, despite recent negative EPS revisions.
Material risks
- 1Prelude Therapeutics is currently unprofitable and is not projected to achieve profitability within the next three years, indicating ongoing cash burn and potential need for further capital raises.
- 2The company's shareholders have experienced substantial dilution over the past year, with total shares outstanding increasing by 32.4%, which could continue with future equity offerings.
Verdict reasoning
While insider buying and analyst upside are strong signals, the company's unprofitability and history of shareholder dilution present considerable risks.